Diabetes and Diabetic Complications: Major World Markets

Countries covered: Global

 

Special Offer. Now 25% off the original price of $3500.

The global market for diabetes products, particularly new therapeutics and monitoring products, is a large and growing one. This growth is fueled by three factors --- (1) a rapidly increasing patient population; (2) a back-log of unmet needs, particularly with regard to therapeutics; and (3) advances in biomedical technology that are making possible new products to serve these unmet needs. In this report from Kalorama, the technological and market dynamics of the expanding diabetes markets are analyzed and discussed to give the reader the information necessary to compete in this dynamic field.

Diabetes and its Major Long-Term Complications in Key World Markets assesses the diabetes markets in the seven major world healthcare markets - the United States, France, Germany, Italy, Japan, Spain and the United Kingdom. It discusses the epidemiology of the disease and current attitudes and methods addressing the treatment of both Type 1 and Type 2 diabetes as well as the major long-term complications of diabetes, including hypertension, dyslipidemia, renal complications and neuropathies. Also covered are some of the emerging approaches to the prevention of diabetes and its complications.

The report discusses in detail the newest scientific and technological breakthroughs affecting these markets including new methods of insulin delivery, non-invasive glucose monitoring and new class of antidiabetic drugs. It presents information on the latest products in the field and the emerging product pipeline, as well as detailed analyses of key competitors in the marketplace.

Additional Information

This report focuses on the market applications of current and advanced technology to the development of monitoring and therapeutic products used in the treatment of diabetes (Type 1 and Type 2) and its major complications. It considers the options that they present, the progress that is being made in these fields, and the reception these new products are likely to experience in the marketplace. The major market effects of new diabetes monitoring products and advanced therapeutics are expected to begin to be seen in the relatively short term, that is, within two to three years. The technology trends selected in conjunction with the growing interest in diabetes, diabetic complications and their treatment present the most informative picture of advances in therapeutics for diabetes and diabetic complications, and the markets that result.

This report covers both current therapeutics and current blood glucose monitoring products, in a broad sense. It does not go into the detail of the dynamics of these various products in the marketplace, either branded (proprietary) or generic in the case of drugs. The ability to do so is limited by several factors, and is especially limited where drugs for the treatment of diabetes complications are concerned. For example, antihypertensives and vasodilators used in the treatment of diabetic complications also have broad use in non-diabetic patients. In some cases, they may also have multiple on- and off-label applications for which it is not possible to discriminate among in the marketplace. Moreover, there is mixture of branded and generic products used in the treatment of diabetes and its complications.

This report does discuss, however, the impacts that advanced technologies and applications will have on existing therapeutics markets in the whole. In general, it is the current products and technologies used in the marketplace, leaving significant unmet need, that have placed today’s market in a position that is vulnerable to new technologies and products.

Market analysis for this report considers the diabetes (Type 1 and Type 2) therapeutics and home monitoring markets, as well as the markets for drugs treating the major complications of diabetes in the seven major world healthcare markets:

• United States
• France
• Germany
• Italy
• Japan
• Spain
• United Kingdom

This report does not consider the “downstream” effects of these complications and the needs for certain types of therapeutic equipment and drugs. For example, diabetic foot is a downstream event of peripheral vascular disease resulting from long-term diabetes. While this report discusses the treatment and prevention of peripheral vascular disease, it does not follow on to products used in the treatment of diabetic foot or any of the other sequellae of diabetic peripheral vascular complications. Some mention is made of the need for therapeutic products in this and other areas, but they are not covered in depth. In terms of diabetes home monitoring, the emphasis is on glucose monitoring because this is the major opportunity market in diabetes monitoring. There are other testing areas: ketones and microalbumin. These are not strong market opportunities, however, and represent small markets that are already well served. As a result, they are mentioned but not analyzed in detail.

The focus of the report is on pharmaceutical-based technologies and products with the potential to become first-line monitoring and therapeutic modalities specifically for Type 1 and Type 2 diabetes and their major direct, long-term complications. The analysis presented in this report is based on data from a combination of company, government, industry, institutional, and private sources. It includes information from extensive literature reviews, as well as interviews and discussions with experts in the field, including diabetologists, endocrinologists, internists, pathologists, research scientists, business development managers and marketing managers.